/PRNewswire/ Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 94.2 million in the fourth quarter of 2021 (Q4 2020: NOK 97.7 million)..
/PRNewswire/ Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 94.2 million in the fourth quarter of 2021 (Q4 2020: NOK 97.7 million)..
/PRNewswire/ Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 88.9 million in the second quarter of 2021 (Q2 2020: NOK 53.5), and.
®/Cysview
® revenues of NOK 81.6 million in the first quarter of 2021 (Q1 2020: NOK 54.4 million), and EBITDA of NOK 18.1 million (NOK -4.8 million), following the continued successful launch in markets previously operated by Ipsen Pharma SAS. The third Covid-19 wave impacted operations in the quarter, but a strong March performance indicates the environment is improving. For the first quarter of 2021, Photocure delivered a 50% YoY increase in Hexvix/Cysview sales, unit growth in our U.S. segment, and positive EBITDA driven by the added revenue in Europe, cost containment, and the payment from Asieris to license Hexvix in China and Taiwan. I am pleased with this performance, particularly given the negative impact from the third wave of Covid-19 in January and February of this year, foreign currency headwinds during the quarter, and the difficult comparison to the same period last year when pandemic lockdowns and limited access to care did not occur until mid-March. While access
Photocure ASA: Results for the first quarter of 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.